Researchers at the University of California, San Diego, the Medical University of South Carolina, the University of Cincinnati, and American Life Science Pharmaceuticals of San Diego have validated the protease cathepsin B (CatB) as a target for improving memory deficits and reducing the pathology of Alzheimer’s disease (AD) … Read the full story from the UCSD Newsroom

Read the abstract of the study report in the Journal of Alzheimer’s Disease

Dr. Vivian Hook
Study co-investigator Vivian Y. H. Hook, PhD, is professor in the departments of neurosciences and pharmacology and professor of medicine in the Division of Nephrology-Hypertension.

Related story: Potential New Drug Candidate Found for Alzheimer’s Disease, May 31, 2011

%d bloggers like this: